FDA Puts Black Box Warning On Power Morcellators With Immediately-In-Effect Guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA has followed through on the advice of its advisory panel by requiring new labeling for power morcellators used to treat uterine fibroids, emphasizing the procedure’s potential to spread cancer. FDA wants to restrict the power morcellation procedure to younger women who are interested in maintaining their ability to have children and who have been thoroughly informed of the risks.
You may also be interested in...
Power Morcellator Use Increases Cancer Risk, FDA Verifies
There is a 1-in-225 to 1-in-580 risk that women getting fibroid removal surgery through hysterectomies or myomectomies may have hidden uterine sarcomas, US FDA said Dec. 14, and verified that power morcellation use during the surgeries will result in higher rates of cancer recurrence.
Ultrasonic Aspirator Guidance Requires Warning On Uterine Use
Manufacturers of 510(k)-cleared ultrasonic aspirators have 120 days to add labeling to the products that warns against use to remove uterine fibroids.
Dr. Amy Reed, Anti-Power Morcellator Activist, Dead At 44
Anesthesiologist Amy Reed, who with her cardiologist husband Hooman Noorchasm turned her battle against uterine cancer into a crusade to abolish unsafe uses of power morcellators, died May 24 at her home in Yardley, Pa., at the age of 44.